Genzyme To Collaborate With China’s Sunway Biotech On Gene Therapy Product
This article was originally published in PharmAsia News
SHANGHAI - Genzyme and Sunway Biotech announced Oct. 25 a collaboration to develop, manufacture and commercialize Ad2/HIF-1a, an experimental gene therapy product, in China
You may also be interested in...
Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.
2016 is the year for precision medicine therapies to be included in China’s National Major Project for Innovation. Looking to seize market opportunity in the newly funded area, Huapont Life Sciences has linked up with and invested in a US bioventure partner for a gene therapy for refractory angina.
SHANGHAI - Genzyme will invest $90 million to build a new R&D center in Beijing's Zhongguancun Life Science Park, the company announced April 22. The 200,000 square-foot center is expected to be operational by 2010 and will have 350 employees working in it